key: cord-0888904-vyg4syog
authors: Chacko, Binila; Thomas, Lovely; Sharma, Roshni; Yadav, Bijesh; Jeyaseelan, Lakshmanan; Arul, Ashwin O.; Victor, Punitha; Chandiraseharan, Vignesh K.; Lenin, Audrin; Carey, Ronald AB.; Jayakaran, Jonathan AJ.; Krishnaswami, Rajiv K.; Peter, John Victor
title: Non-invasive Ventilation (NIV) in the Management of Respiratory Failure Due to COVID-19 Infection: Experience From a Resource Limited Setting
date: 2021-10-13
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.10.002
sha: db841597d48cab4f1128989f149f9b0315608d94
doc_id: 888904
cord_uid: vyg4syog

Introduction The role of NIV in SARS-CoV2 (COVID-19) related acute respiratory failure (C-ARF) is unclear. Methods C-ARF patients managed on NIV were categorised as NIV success or failure (death or intubation). Factors associated with failure were explored using regression analysis and expressed as Odds ratio (OR) with 95% Confidence Interval (CI). Results Between 1st April 2020 and 15th September 2020, 286 patients, age (Mean, SD) 53.1±11.6 years and APACHE-II score 11.1±5.5 were initiated on NIV. Of the 182 patients (63.6%) successfully managed on NIV alone, 118 had moderate or severe Acute Respiratory Distress Syndrome (ARDS). When compared with NIV success, NIV failure was associated with lower admission PaO2/FiO2 ratio (p<0.001) and higher respiratory rate (p<0.001). On penalized logistic regression analysis, NIV failure was associated with higher APACHE (OR 1.12; 95%CI 1.01-1.24), severe ARDS (OR 3.99; 1.24-12.9), D-dimer ≥1000 ng/ml (OR 2.60; 1.16-5.87), need for inotropes or dialysis (OR 12.7; 4.3-37.7) and nosocomial infections (OR 13.6; 4.06-45.9). Overall mortality was 30.1%. In patients requiring intubation, time to intubation was longer in non-survivors than survivors (Median IQR 5 (3-8) vs. 3 (2-3) days, p<0.001). Conclusions NIV can be used successfully in C-ARF. Illness severity and need for non-respiratory organ support predict NIV failure.

Non-invasive ventilation (NIV) has an important role in the management of respiratory failure of diverse aetiology (1) . NIV was not recommended for SARS-CoV2 (COVID- 19) related acute respiratory failure (C-ARF) during the initial phase of the pandemic given the aerosol generating potential (2) (3) and the inconsistent reports of benefit from previous pandemic experiences (4)(5)(6) (7) . Reports indicate that COVID-19 patients who required invasive mechanical ventilation, fared poorly and had a fatality rate of over 50% (8) .

In a large study of 1591 patients admitted to the intensive care unit (ICU) with COVID-19 (9) , 1287 of the 1300 patients analysed (88%) required respiratory support; only 137 patients (11%) were managed with NIV. ICU mortality was 26%. In this study, no exploratory analysis was provided on the subset of patients treated with NIV. In a recent cohort of 416 ICU patients (10) , in whom the overall mortality was 38.2%, mortality was significantly higher (p<0.001) with invasive ventilation (104/113; 92%) than with NIV (62/152; 40.8%). This study did not report failure rate with NIV nor explore the characteristics that predicted NIV success in COVID-19. Recent publications have suggested a role for NIV in the non-ICU setting (11) (12) (13) (14) (15) (16) (17) .

There are several challenges to the provision of positive-pressure ventilation in resource limited settings given the lack of negative pressure rooms, the inability to scale up resources rapidly and the cost involved in prolonged invasive ventilation. In this context, despite the initial concerns on the potential risk with NIV, a conscious decision was made in our institution to use NIV in an attempt to reduce the need for invasive ventilation. This study was undertaken to evaluate the success rate of NIV in patients admitted to the ICU with C-ARF and to explore the factors associated with NIV failure.

This study was done in the medical ICU in a 2800-bed tertiary care university affiliated teaching hospital in South India, which was rapidly up-scaled from 2 to 4 ICU pods and from 24 to 50 beds during the pandemic. A total of 258 healthcare workers (HCWs) were involved in the care of critically ill C-ARF patients. Patients requiring NIV at the time of ICU admission or during the course of ICU stay, were prospectively enrolled between 1 st April 2020 and the 15 th September 2020, and followed up till death or discharge from hospital. The study was approved by the Institutional Review Board and Ethics Committee of the hospital (IRB No: 12743, dated 1.5.2020) and consent was obtained from the patient or next of kin.

Demographic data, co-morbidities, treatment and outcomes were recorded. Treatment included anti-viral therapy (Remdesivir), and anti-coagulation (either prophylactic or therapeutic). Therapeutic anticoagulation was considered if D-Dimer was >1000 ng/ml in the setting of worsening respiratory status with or without proven thrombotic events. Although corticosteroids were introduced to the standard protocol in July 2020 when the evidence for its use was published (18) , clinicians used corticosteroids based on some evidence of benefit in other clinical settings. Hydroxychloroquin (HCQ) was not used in our patients as per the treatment guidelines followed in our institution. Other adjunct therapies were recorded.

Patients were initiated on NIV if they had evidence of respiratory failure with increasing tachypnea (respiratory rate > 24/min) and/or signs of increased work of breathing with accessory muscle use and were hemodynamically stable, conscious and co-operative (1).

NIV was provided in the ICU using mechanical ventilators designed for invasive ventilation via a facemask; dedicated NIV machines and portable devices were not used due to the problems of titrating fixed inspired oxygen (FiO2) and the limitations in fine-tuning patientventilator synchrony. Continuous Positive Airway Pressure (CPAP) mode was not considered as NIV. The pressure support was titrated to achieve a tidal volume of around 6 ml/kg; J o u r n a l P r e -p r o o f positive end expiratory pressure (PEEP) and FiO2 were adjusted to achieve a saturation of over 92%. Awake proning was encouraged.

Patients who failed trial of NIV (worsening work of breathing, worsening PaO2/FiO2 ratio and/or increasing respiratory rate despite adequate ventilatory support) and patients with increasing hemodynamic instability, low Glasgow Coma Scale (GCS<8) or impending respiratory or cardiac arrest were intubated, unless there was clear directive for nonescalation of care either from the patient or the next-of-kin. The decision to intubate was not limited based on practical logistic considerations. Although broad guidelines for criteria for intubation were defined at the start of the pandemic and refined subsequently, based on our understanding of the role of NIV in COVID (Figure 1 ), intensivists were allowed to use clinical discretion on the timing of intubation as well as the thresholds. Patients who were intubated and ventilated received analgo-sedation and other organ support as required.

Nosocomial infections and ventilator related adverse events were diagnosed and managed as per guidelines (19) . Since the ICU areas did not have facilities for negative pressure and had limited isolation rooms (n=4), the remaining patients were cohorted in the common ICU areas. The units were modified to allow for 8 to 12 air-exchanges every hour in an attempt to reduce the viral load within the unit. HEPA (High Efficiency Particulate Air) filters were fitted to the exhaust system in the air-handling unit. In addition, viral filters were connected to the expiratory port of the ventilator. All healthcare workers (HCW) in the ICU were provided HAZMAT suits, N95 masks and eye protection (goggles or visors) and the duration of the shifts were restricted to a maximum of 8-10 hours. The proportion of HCW in the ICU who became symptomatic and were tested positive for SARS-CoV2 during the study period was also recorded.

Statistical methods: No sample size calculation was performed a priori as this was set out as a time-frame study to record the initial observations on NIV in a resource limited setting. The success rate with NIV was defined as the proportion of patients who were successfully weaned off NIV without the need for invasive mechanical ventilation and were discharged alive from hospital. Summary data were presented as mean (standard deviation, SD) for normally distributed data and as median (interquartile range, IQR) if data were skewed. The characteristics of patients who failed or succeeded with NIV were compared using t-test and Mann-Whitney U test for continuous data and categorical data were compared using Chisquare/Fisher's exact test as appropriate. Factors associated with NIV failure (p<0.2) on univariate analysis were considered for the multivariable regression analysis. Penalized logistic regression analysis was used (21) (22) for multivariable analysis in order to get reliable Odds Ratio (OR) and 95% Confidence Interval (CI), since some covariates such as need for inotropes and dialysis had few cell counts. Since many parameters were collinearly related (e.g. length of ICU and hospital stay, APACHE-II and SOFA scores, ventilation data) and some variables were clinically insignificant (values in the normal range or just outside J o u r n a l P r e -p r o o f range) despite being statistically significant (e.g. Troponin, LDH), nine clinically relevant and statistically significant variables were considered for the penalized logistic regression.

Given the clinical correlation of rising D-dimer and worsening respiratory status, peak (rather than admission) D-dimer values were used in the regression analysis. Statistical significance was defined as p<0.05. All analyses were performed using STATA v15 and SPSS v25.

Baseline demographic data: During the study period, 351 patients were admitted to the ICU; 333 patients had C-ARF ( Figure 2 ). 286 of these patients with a mean (SD) age of 53.1 (11.6) years, who were initiated on NIV for respiratory failure, formed the study cohort. The mean (SD) APACHE-II score was 11.1 (5.5); 57.3% had 2 or more co-morbidities. The predominant symptomatology was fever (82.2%), breathlessness (74.5%) and cough (64.7%).

The mean (SD) lag time to ICU admission from symptom onset was 6.8 Table 1) . Thirteen patients (4.4%) with C-ARF did not fulfil the diagnostic criteria for ARDS.

Lymphocyte ratio (NLR) was 9.2 (5.7, 15) and the D-dimer was 809 ng/ml (506, 1432).

There was no evidence of cardiac enzyme elevation or increased creatinine at admission (Table 1) The overall mortality in patients who were initiated on NIV was 30.1% (86/286, 95%CI 24.9 to 35.8%). The median (IQR) duration of ventilation of the cohort was 8 (5, 13) days, of which NIV was used for 5 (3, 8) days and invasive ventilation for 11 (7, 18) days.

The median (IQR) time to intubation after ICU admission in this cohort was 4 (2, 7) days.

Acute kidney injury (AKI) developed in 20.6% and 7% required dialysis; 23.1% developed nosocomial infections. Eleven patients (3.9%) had proven thrombotic complications while on anti-coagulation; 4% of this cohort had minor bleeds and only 1% J o u r n a l P r e -p r o o f had major bleeds that required transfusion. The median (IQR) ICU length of stay was 9 (6, 15) days and the hospital length of stay was 16 (12, 23) days.

Factors associated with NIV failure: When compared with NIV success, NIV failure was significantly associated with (Table 1) older age, higher disease severity, lower admission PF ratio, higher respiratory rate, higher CK-MB, need for organ support, longer duration of continuous NIV and longer ICU and hospital length of stay.

On adjusted penalized logistic regression analysis ( PF ratio and respiratory trends among NIV success and failure: The patients in this cohort had pure hypoxemic respiratory failure. In the group successfully managed with NIV, the PF ratio ( Figure 3 ) steadily improved from day 3 onwards. After day 5, there was a marginal drop in PF ratio, probably reflecting weaning from NIV. In contrast, in the NIV failure group, the PF ratio remained almost static in the first three days. In the subset of NIV failure that survived, there was a dramatic increase in PF ratio from day 3 to 5, while in those who died, PF ratio continued to remain low (Figure 3 ). In patients requiring intubation, time to intubation was longer in non-survivors when compared with survivors (Median IQR 5 (3) (4) (5) (6) (7) (8) vs. 3 (2-3) days, p 0.001). With regards to trends in respiratory rate, all three subsets of patients had a reduction in respiratory rate over the first 3 to 5 days (Figure 4 ). There was a greater reduction in the respiratory rate in the NIV success and NIV failure arms who survived than in those who died, where the respiratory rate remained high even after 7 days.

Factors associated with mortality: On unadjusted penalized logistic regression analysis, several factors were associated with mortality (Table 3) . On adjusted analysis ( 

In this study spanning 6-months, over 80% of patients (286/351) admitted to the ICU were initiated on NIV. While the overall mortality in this NIV cohort was 30.1%, the mortality in those managed exclusively on NIV was 10.8% as opposed to 79% in those who failed NIV and needed intubation. NIV success rate was 63.6% (n=182), of whom two-thirds had moderate (n=85) or severe (n=33) ARDS. NIV failure was associated with higher APACHE-II scores, severe ARDS, longer duration of continuous NIV, peak D-dimer ≥1000 ng/ml, need for non-pulmonary organ support and nosocomial infections.

The role of NIV in the treatment of C-ARF is debated (15) , because of the potential for aerosol generation (23), the nature of respiratory failure (predominantly hypoxemic) (17) (24) and the protracted course of illness. The concern also stems from evidence of NIV failure in ARDS of diverse aetiology ranging from 22% (25) to as high as 92.4% (4), and conflicting results on the role of NIV from studies during the H1N1 and SARS pandemics (5)(6)(7).

Despite the controversies surrounding the safety and benefit of NIV in C-ARF, with the increasing burden of C-ARF that overwhelmed ICU capacity, NIV use increased from J o u r n a l P r e -p r o o f 11% in the early months of the pandemic (9)(26) to 56% (27) as time progressed. Further, the hypothesis that NIV may play a role in reducing the progression from the L phenotype of C-ARDS to the H phenotype (28) could have also contributed to increased use.

In most of the studies published so far, NIV was delivered in a non-ICU setting (Table 4 ). Data on the utilization of NIV in the ICU setting and its predictors of success is however limited. To the best of our knowledge, this is the largest ICU-based study that has explored the role of NIV in terms of effectiveness in consecutive patients with C-ARF. In this study, an overwhelming majority (>85%) of patients who presented with C-ARF were initiated on NIV irrespective of severity of ARDS. This contrasts the subgroup analysis of the LUNG SAFE study where the NIV subgroup had a high failure rate (defined as the need for intubation) and death among patients with moderate to severe ARDS (25) .

In this cohort, 104 (36.4%) patients failed NIV (Table 1) . NIV failure rate in the various studies ranged from 30.7% (12) to 62% (13) ( Table 4) It was interesting to note that the PF ratios in the current study increased to over 200 by day 3 in the NIV success subgroup as opposed to day 5 in the subgroup that survived intubation after a failed NIV trial. In contrast, the subgroup that failed NIV and died, PF ratios remained relatively static during the entire 1 st week following ICU admission ( Figure   3 ). Our observations are consonant with that of Faraone et al (13) who reported that increasing PF ratios 24 to 48 hours after NIV initiation may help in identifying potential NIV responders.

The mortality of the entire cohort was 30.1%; notably the mortality was quite low . Mortality in the other NIV cohorts ranged from 23.1% (12) to 74% (15) . It is however concerning that the NIV failure arm that required intubation had higher mortality (78%) when compared with the group that required immediate intubation (61.5%) in the ICU (Figure 2 ).

On exploratory analysis, it was observed that the time to intubation was significantly longer in non-survivors when compared with survivors (Median IQR 5 (3-8) vs. 3 (2-3) days, p<0.001), suggesting that delay in intubation in those on NIV may contribute to mortality. This contrasts the study by Daniel et al (15) and the meta-analysis by Papoutsi et al (24) that suggested that timing of intubation had no effect on mortality.

In the early stages of the pandemic, it was observed that a combination of factors (increasing fraction of inspired oxygen requirement (FiO2), persistently high FiO2 >70%, PF ratio <100 and increased work of breathing whilst on continuous NIV seemed to affect the outcomes of patients who were intubated after a failed NIV trial. Based on these observations, the guidelines for the thresholds for intubation were dynamically re-defined over time. This finally resulted in the reduction of the FiO2 threshold for intubation from 70% to 60% (in the context of a PF ratio of <100) and the increasing work of breathing was made an optional criteria (+/-) rather than a mandatory criteria ( Figure 1 ). However, as stated in the methods, these protocols were offered as guidelines and the actual decision on intubation was taken by the treating intensivist based on the clinical assessment. These modifications in the ventilatory protocol may have positively impacted outcomes in our study. The optimal timing of intubation however warrants further study. While it may be challenging to plan a trial of early vs. delayed intubation, it will be interesting to see if there is greater clarity on the timing of intubation in COVID-19 ARDS from large datasets. HCWs contributed up to 12% of reported COVID-19 cases (13) . In our cohort, NIV was delivered exclusively using oro-nasal facemasks; helmet interfaces were not used.

Antimicrobial filters were applied to the exhalation port in the ventilators to limit SARS-CoV-2 spread (30) .

The study has the following limitations. This was an observational study from a single centre ICU. The lack of a control group precludes definite conclusions on benefit of NIV on patient outcomes over early intubation. It would have been useful to collect expiratory tidal volume data and use the HACOR score to predict NIV failure (31); these were not done.

Nevertheless this study shows that a significant proportion of patients who present with C-ARDS can be successfully managed on NIV.

This study adds to the body of evidence that NIV can be effective as a primary ventilatory support in patients with C-ARF in the ICU. NIV was successful in nearly two-thirds of patients with C-ARF and can be used even in patients with moderate to severe ARDS. Illness severity, prolonged requirement of continuous NIV, need for non-respiratory organ support, peak D-dimer ≥1000 ng/ml and development of nosocomial infections predict NIV failure.

Further studies are required to clarify the optimal timing of intubation in those who do not improve with NIV. Those patients who were successfully managed on NIV had lower admission respiratory rate, when compared with patients who were failed NIV but survived and those who failed NIV and died. All three subsets of patients had a reduction in respiratory rate over the first 3 to 5 days. There was a greater reduction in the respiratory rate in the NIV success and NIV failure arms who survived than in those who died, where the respiratory rate remained high after 7 days and did not come down further.

J o u r n a l P r e -p r o o f 2) were considered for the adjusted penalized logistic regression. However since many parameters were collinearly related (e.g. length of ICU and hospital stay, APACHE-II and SOFA scores, several ventilation characteristics) and some of the statistically significant variables were not clinically significant in terms of actual values being in the normal range or just outside the range (e.g. Troponin, LDH), nine clinically relevant and statistically significant variables were considered for the penalized logistic regression.

J o u r n a l P r e -p r o o f Table 3 : Adjusted analysis of factors associated with mortality APACHE -Acute Physiology and Chronic Health Evaluation; SOFA -Sequential Organ Failure Assessment; ARDS -Acute Respiratory Distress Syndrome; OR -Odds ratio; CI -Confidence Interval; NIV Non-invasive ventilation; factors identified on unadjusted regression analysis (p<0.2) were considered for the adjusted penalized logistic regression. However since many parameters were collinearly related (e.g. APACHE-II and SOFA scores, several ventilation characteristics) and some of the statistically significant variables were not clinically significant in terms of actual values being in the normal range or just outside the range (e.g. Troponin, LDH), nine clinically relevant and statistically significant variables were considered for the penalized logistic regression. 

Non-invasive ventilation in acute respiratory failure

Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses

Noninvasive versus invasive mechanical ventilation for respiratory failure in severe acute respiratory syndrome

Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome

Early noninvasive ventilation treatment for severe influenza pneumonia

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Invasive mechanical ventilation in COVID-19 patient management: the experience with 469 patients in Wuhan. Crit Care

Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre

Outcome of noninvasive ventilation in COVID-19 critically ill patients: A Retrospective observational Study

Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-hypoxemic respiratory failure: a single center, non-ICU setting experience

Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19

Noninvasive positive pressure ventilation versus endotracheal intubation in treatment of COVID-19 patients requiring ventilatory support

Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry

Effectiveness of noninvasive ventilation in COVID-19 related-acute respiratory distress syndrome

Dexamethasone in Hospitalized Patients with Covid-19

Types of Healthcare-associated Infections | HAI | CDC

Acute respiratory distress syndrome: the Berlin Definition

Analysis of sparse data in logistic regression in medical research: A newer approach

Firth's logistic regression with rare events: accurate effect estimates and predictions? Stat Med

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study

Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19

Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients